AIM ImmunoTech Inc. announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen(R) as a potential therapeutic for people with post-COVID conditions ("AMP-518"). The study has met the planned enrollment of 80 AMP-518 subjects ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two weeks. The ompany expects to complete dosing of the last study patient in Fourth Quarter 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 USD | -3.00% | -4.47% | -12.48% |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
04-29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.48% | 19.59M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions